Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.69 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.69 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.66 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.66 |
| ▸ | GSR | P00390 | 1/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.57 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.57 |
| ▸ | NOS2 | P35228 | 2/20 | 0.56 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.56 |
| ▸ | ARG2 | P78540 | 4/20 | 0.55 |
| ▸ | ARG1 | P05089 | 3/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7889574 | 1.00 | GRIK1 (0.69) | GRIK1GRIK2SLC1A2SLC1A1GSR | |
| SCHEMBL7878467 | 1.00 | GRIK1 (0.69) | GRIK1GRIK2SLC1A2SLC1A1GSR | |
| SCHEMBL660684 | 1.00 | GRIK1 (0.69) | GRIK1GRIK2SLC1A2SLC1A1GSR | |
| SCHEMBL3689310 | 1.00 | GRIK1 (0.69) | GRIK1GRIK2SLC1A2SLC1A1GSR | |
| SCHEMBL1527353 | 1.00 | GRIK1 (0.69) | GRIK1GRIK2SLC1A2SLC1A1GSR | |
| SCHEMBL1738925 | 1.00 | GRIK1 (0.69) | GRIK1GRIK2SLC1A2SLC1A1GSR | |
| SCHEMBL23531056 | 1.00 | GRIK1 (0.69) | GRIK1GRIK2SLC1A2SLC1A1GSR | |
| SCHEMBL5048329 | 1.00 | GRIK1 (0.69) | GRIK1GRIK2SLC1A2SLC1A1GSR | |
| SCHEMBL1960915 | 1.00 | GRIK1 (0.69) | GRIK1GRIK2SLC1A2SLC1A1GSR | |
| SCHEMBL10579474 | 1.00 | GRIK1 (0.69) | GRIK1GRIK2SLC1A2SLC1A1GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118440156-A | Bionic cyclic peptide and application thereof | 郑州大学第一附属医院 | 2024-08-06 | — | — | CN | claimed |
| US-5498786-A | Synthesis of intermediates in the preparation of ACAT inhibitors | PFIZER INC. (US) | 1996-03-12 | — | — | US | claimed |
| EP-0569482-B1 | SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ACAT INHIBITORS | PFIZER (US) | 1995-08-02 | — | — | EP | claimed |
| WO-1992013843-A1 | SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ACAT INHIBITORS | PFIZER INC. (US) | 1992-08-20 | — | — | WO | claimed |
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118440156-A | Bionic cyclic peptide and application thereof | 郑州大学第一附属医院 | 2024-08-06 | — | — | CN | disclosed |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-3981784-A1 | REGULATORS OF CELL DIVISION | Technische Universität Dresden (DE) | 2022-04-13 | — | — | EP | disclosed |
| US-20210179538-A1 | METHOD FOR PRODUCING 2-OCTYLGLYCINE ESTER HAVING OPTICAL ACTIVITY | AMINOLOGICS CO., LTD. (KR) | 2021-06-17 | — | — | US | disclosed |
| EP-3725766-A1 | METHOD FOR PRODUCING 2-OCTYLGLYCINE ESTER HAVING OPTICAL ACTIVITY | Aminologics Co., Ltd. (KR) | 2020-10-21 | — | — | EP | disclosed |
| WO-2012051663-A1 | ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2012-04-26 | — | — | WO | disclosed |
| WO-2010130007-A1 | ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2010-11-18 | — | — | WO | disclosed |
| US-5498786-A | Synthesis of intermediates in the preparation of ACAT inhibitors | PFIZER INC. (US) | 1996-03-12 | — | — | US | disclosed |
| EP-0569482-B1 | SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ACAT INHIBITORS | PFIZER (US) | 1995-08-02 | — | — | EP | disclosed |
| WO-1992013843-A1 | SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ACAT INHIBITORS | PFIZER INC. (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | GRIK1 4429/4885GRIK2 4474/4885SLC1A2 2617/4885 |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | HAVCR2, HDGF, SLC10A1 | GRIK1 4355/4885GRIK2 4345/4885SLC1A2 2588/4885 |
| US-20210179538-A1 | METHOD FOR PRODUCING 2-OCTYLGLYCINE ESTER HAVING OPTICAL ACTIVITY | GNMT, UGT8, OPRM1 | GRIK1 376/4885GRIK2 335/4885SLC1A2 437/4885 |
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | PCNA, BOD1L1, MKI67 | GRIK1 4292/4885GRIK2 4454/4885SLC1A2 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.